2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
4
Recruiting
3
Active not recruiting
3
Unknown
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
562
Specimen Handling
490
Carboplatin
451
Magnetic Resonance Spectroscopy
444
Cyclophosphamide
418
Cisplatin
406
Radiotherapy
353
Gemcitabine
314
Bevacizumab
313
Paclitaxel
298
Biopsy
290
Drug Therapy
283
Blood Specimen Collection
248
Capecitabine
245
Oxaliplatin
241
fludarabine
240
Nivolumab
234
venetoclax
221
Injections
213
Docetaxel
211
Fluorouracil
205
Dexamethasone
187
Radiosurgery
182
Rituximab
159
Standard of Care
158
Pemetrexed
156
Surgical Procedures, Operative
148
durvalumab
145
atezolizumab
145
Leucovorin
139
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Histamine Antagonists
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled